UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012144
Receipt number R000014178
Scientific Title Effect of twice daily rabeprazole treatment on sleep disturbances in GERD patients with once daily PPI
Date of disclosure of the study information 2013/10/28
Last modified on 2013/10/28 14:29:06

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of twice daily rabeprazole treatment on sleep disturbances in GERD patients with once daily PPI

Acronym

Effect of PPI on sleep disturbances in patients with GERD

Scientific Title

Effect of twice daily rabeprazole treatment on sleep disturbances in GERD patients with once daily PPI

Scientific Title:Acronym

Effect of PPI on sleep disturbances in patients with GERD

Region

Japan


Condition

Condition

gastroesophageal reflux disease

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

we examine the effect of PPI on sleep disturbances in patients with GERD by using actigraph and electroencephalograph(EEG).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

parameters by actigraph

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Randomized

Randomization unit


Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rabeprazole sodium (10mg)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

A diagnosis of erosive GERD including gradeM was made by the endoscopic examination before the PPI dosage start.
The patient who takes a rabeprazole sodium 10mg in the morning after the diagnose of GERD.
Patient having less than 95% of % SLEEP by actigraph.

Key exclusion criteria

They were pregnant or nursing mother, or used atazanavir sulfate, or had allergy to rabeprazole sodium, Zollinger-Ellison syndrome and peptic ulcer disease.
Disease-related exclusion criteria included the following: severe disease of any major body system; malignant disease of any kind; gastrointestinal diseases such as esophageal stricture, primary esophagus motor disorders, systemic sclerosis, severe sleep disorder, depression or any other psychiatric disease associated with worsened QOL, past history of upper gastrointestinal surgery.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuhiro Fujiwara

Organization

Osaka City University Graduate School of Medicine

Division name

Osaka City University Graduate School of Medicine

Zip code


Address

1-4-3 Asahi-machi, Abeno-ku,Osaka 545- 8585, Japan

TEL

06-6645-3811

Email

yasu@med.osaka-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Keiko Hiramoto

Organization

Osaka City University Graduate School of Medicine

Division name

Osaka City University Graduate School of Medicine

Zip code


Address

1-4-3 Asahi-machi, Abeno-ku,Osaka 545- 8585, Japan

TEL

06-6645-3811

Homepage URL


Email

m2039002@med.osaka-cu.ac.jp


Sponsor or person

Institute

Osaka City University Hospital

Institute

Department

Personal name



Funding Source

Organization

no

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2013 Year 10 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2013 Year 09 Month 01 Day

Date of IRB


Anticipated trial start date

2013 Year 09 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 10 Month 28 Day

Last modified on

2013 Year 10 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014178


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name